One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Table of Contents
doi : 10.1016/S0923-7534(24)04036-5
Volume 35, Issue 11, November 2024, Pages i-ii
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer?
TNT for organ preservation in rectal cancer: still looking for the right schedule and patient
Paving the path towards tissue-agnostic drug approval in oncology
Elevating cancer on the global health agenda: towards the fourth high-level meeting on NCDs 2025
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer☆
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial☆
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022☆
Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY☆
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma☆
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later
Advancing rectal cancer therapy: mFOLFIRINOX reduces metastasis and improves survival outcomes. Letter to the Editor regarding ‘Total neoadjuvant therapy with mFOLFIRINOX versus preoperativechemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial’ by Conroy T et al.
Interpretation of long-term overall survival from the PRODIGE 23 study. Letter to the Editor regarding ‘Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial’, by T. Conroy et al
Efficacy rigor of neoadjuvant therapy: the role and synthesis of tumor subtype analysis. Letter to the Editor regarding ‘Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial’ by Conroy T et al.
